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Abstract
Although reported gene variants in the RET oncogene have been directly associated with multiple endocrine neoplasia type
2 and hereditary medullary thyroid carcinoma, other mutations are classified as variants of uncertain significance (VUS) until
the associated clinical phenotype is made clear. Currently, some 46 non-synonymous VUS entries exist in curated archives.
In the absence of a gold standard method for predicting phenotype outcomes, this follow up study applies feature selected
amino acid physical and chemical properties feeding a Bayes classifier to predict disease association of uncertain gene
variants into categories of benign and pathogenic. Algorithm performance and VUS predictions were compared to
established phylogenetic based mutation prediction algorithms. Curated outcomes and unpublished RET gene variants with
known disease association were used to benchmark predictor performance. Reliable classification of RET uncertain gene
variants will augment current clinical information of RET mutations and assist in improving prediction algorithms as
knowledge increases.
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Introduction
Medical genetics involves diagnosis, management, and deter-
mining risk of hereditary disorders [1,2]. The genotype:phenotype
correlation of gene variants in disease is a major component of
medical genetics. In monogenic diseases, gene mutations are
typically curated as either pathogenic or benign. However, many
gene variants must be classified as ‘‘unknown’’ or ‘‘uncertain’’
significance because they have not been clearly associated with a
clinical phenotype.
The outlay of time and labor to validate the disease association
concerning a variant of uncertain significance (VUS) within the
coding portion of a gene can be daunting and cost prohibitive
[3,4]. This is in large part, due to the communication between
clinicians and laboratory geneticists needed to resolve these
variants [5,6]. To help bridge this genotype:phenotype gap, the
use of machine learning classification algorithms to narrow the
uncertain ‘‘grey area’’ between pathogenic and benign sequence
variants warrants careful evaluation [7,8,9,10]. Reliable machine
learning based classification may augment costly patient recruit-
ment, family histories, and biochemical confirmation of a gene
variant with no associated disease correlation [11,12,13].
There are established methods for predicting mutation severity
based on amino acid substitution penalties, structural disruption,
sequence homology (ortholog conservation) or neural nets, such as
PolyPhen [13], SIFT [14], MutPred [9] and PMut [15]. However,
predictionalgorithmsarenotalwaysinagreementwith curateddata
or each other [16,17,18]. Thus, there are opportunities to explore
the use of other informatics approaches to this problem. Machine
learning methods that can be trained on data available in well-
curated gene variant collections may be promising tools to improve
the predictive capabilities available to the research community.
The human RET gene (REarranged during Transfection) is
located on chromosome 10q.11 codes for 20 exons. The transcript
length is 5,659 bps and translates to the 1,114 amino acid residue
protein (UniProt RET_HUMAN, #P07949) as shown in Figure 1.
The gene belongs to the cadherin superfamily and encodes a
receptor tyrosine kinase which functions in signaling pathways for
cell growth and differentiation. RET plays a critical role in neural
crest development. It can also undergo oncogenic activation in vivo
and in vitro by cytogenetic rearrangement. It can be further
classified by Gene Ontology (GO) categories (www.geneontology.
org) of biological process of homophilic cell adhesion, posterior
midgut development, and protein amino acid phosphorylation. Its
GO annotated cellular location is component integral to
membrane and the GO category of molecular functions lists
ATP binding, calcium ion binding and transmembrane receptor
protein tyrosine kinase activity. Functional domains of the RET
protein are also summarized in Figure 1.
RET is essential for the development of the sympathetic,
parasympathetic and enteric nervous systems. Disruption of
function by germline mutations in RET have been associated
with several diseases in humans including three related inherited
cancers: multiple endocrine neoplasia type IIA (MEN2A), multiple
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18380endocrine neoplasia type IIB (MEN2B), and familial medullary
thyroid carcinoma (FMTC). [19,20] RET has also been implicated
in congenital aganglionosis (absence of enteric nerve cells) in the
gastrointestinal tract (Hirschsprung’s disease) lack of the neuroen-
teric plexi impairs smooth muscle activity of the intestines
(particularly the colon) resulting in refractory constipation. [21]
Although well understood codon changes often guide patient
therapy or surgical options [22], RET gene variants may vary in
functional severity, where some are reported as benign, some
pathogenic, and some of uncertain significance. Curated RET
oncogene mutations have been recently reported by Margraf et al.
[23] The disease classification of RET gene variants has been
curated as benign (6%), pathogenic (52%) and VUS (42%),
meaning unknown or uncertain association with disease or
phenotype outcome. This archive currently hosts 146 RET
variants, including 62 VUS entries that can be accessed at
http://www.arup.utah.edu/database/.
Accurate prediction of disease association for novel mutations
and uncertain gene variants is of great importance to medicine and
biology. Informatics tools for predicting disease severity of
uncertain gene variants will aid in the improvement of
genetically-informed patient care. With a rapidly growing number
of on-line resources for gene variants collections, the opportunity
to apply machine learning algorithms to well curated disease
causing gene sets becomes increasingly desirable.
The absence of any gold standard for predicting phenotype
severity in uncertain gene variants prompts two questions. Are
algorithms trained specific to a gene/disease setting more
appropriate to use than generalized on-line prediction tools? Does
agreement between several and varying algorithms influence
clinician decision-making? This study expands a recently reported
algorithm, we here term Primary Sequence Amino Acid Properties
(PSAAP), which uses feature selected amino acid physicochemical
properties of primary amino acid sequence [24]. This previous
work detailed algorithm performance using only gene variants
with known disease association, while here we report applying the
PSAAP algorithm classification for pathogenicity of novel and
uncertain gene variants found in the RET proto-oncogene into
categories of benign or pathogenic. The PSAAP algorithm
performance has also been compared to four well-established
prediction tools available on-line and agreement between
algorithms summarized.
Results
The independent test set of RET curated mutations was used to
evaluate performance of different categories of classifier algo-
rithms. The best performing algorithm (using Weka) was Naı ¨ve
Bayes. Algorithm metrics for this novel Bayes classifier of RET
disease outcome were calculated using the above test set data.
Evaluation of the classifier yielded a sensitivity of 0.938, specificity
of 0.867 and positive predictive value (precision) of 0.883.
Performance for our Primary Sequence Amino Acid Properties
(PSAAP) classifier is summarized in Table 1. A benchmark of
prediction performance for the established algorithms (MutPred,
PolyPhen, PMut and SIFT) was also performed using curated RET
gene variants with known disease outcomes. Following the 88% of
the PSAAP classifier, MutPred was next closest to predicting the
correct disease outcomes for the known RET variants with 84%
precision. PolyPhen yielded the highest specificity for RET variant
disease association of 92%, yet had the lowest precision at 54%.
PMut correctly predicted gene variant disease outcomes with 72%
precision but had the lowest specificity at 59%. Table 1 also
summarizes performance metrics (sensitivity, specificity, precision)
for curated RET mutations using the four established prediction
algorithms.
Next, evaluation of RET non-synonymous VUS mutations
(n=46) was performed using our recently reported algorithm [24].
The PSAAP algorithm classified 22 of the uncertain variants as
pathogenic, while the remaining 24 fell within the benign
Figure 1. Schematic of the full length 1114 amino acid RET protein showing the signal peptide (SP, residues 1-24), cadherin domain
(CAD, residues 191-270), transmembrane domain (TM, residues 636-652), and tyrosine kinase motif (Kinase, residues 724-1005).
doi:10.1371/journal.pone.0018380.g001
Table 1. PSAAP algorithm performance of predicted phenotypes using curated RET mutations.
PSAAP Prediction
a MutPred Prediction
b PolyPhen Prediction
c PMut Prediction
d SIFT Prediction
e
Sensitivity 0.938 0.767 0.597 0.783 0.816
Specificity 0.867 0.823 0.920 0.591 0.821
Precision 0.883 0.843 0.541 0.723 0.779
aPrimary Sequence Amino Acid Properties (PSAAP) algorithm.
bAnalyzed with default settings at http://mutdb.org/mutpred.
cAnalyzed with default settings at http://genetics.bwh.harvard.edu/pph.
dAnalyzed with default settings at http://mmb.pcb.ub.es/PMut.
eAnalyzed with default settings at http://sift.jcvi.org.
doi:10.1371/journal.pone.0018380.t001
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PSAAP algorithm estimated confidence remained above 90%.
The classifier predicted disease outcome using our algorithm is
listed in Table 2.
Results from analysis of the RET uncertain gene variants (VUS)
using the established on-line prediction tools are also summarized
in Table 2, with predicted pathogenic variants bolded and ranked
by agreement. The MutPred tool calculates the probability of a
deleterious mutation and corresponding hypothesis of disrupted
molecular mechanism. We used MutPred’s default probability
cutoff of 0.75 for differentiating between benign and disrupted/
pathogenic mutations. Our PSAAP algorithm agreed with
MutPred in 16 benign and 8 pathogenic predictions for 52%
agreement (24 out of 46). PolyPhen has outcomes of ‘‘benign’’,
‘‘possibly damaging’’ and ‘‘probably damaging’’. The PSAAP
classifier agreed with PolyPhen in 13 benign and 22 pathogenic
Table 2. Algorithm agreement for RET uncertain gene variants and predicted pathogenicity.
RET uncertain gene
variant PSAAP Prediction
a MutPred Prediction
b PolyPhe Prediction
c SIFT Prediction
d PMut Prediction
e
5/5 agreement
A510V
R600Q
K603Q
E632K
A640G
V648I
Y791N
E843D
R844L
R844W
R886W
R912Q
Benign
Benign
Benign
Benign
Benign
Benign
pathogenic
benign
pathogenic
pathogenic
pathogenic
pathogenic
Benign
Benign
Benign
Benign
Benign
Benign
disrupted
Benign
disrupted
disrupted
disrupted
disrupted
Benign
Benign
Benign
Benign
Benign
Benign
probably damaging
benign
probably damaging
probably damaging
probably damaging
probably damaging
Tolerated
tolerated
tolerated
tolerated
tolerated
tolerated
affects function
tolerated
affects function
affects function
affects function
affects function
Neutral
neutral
neutral
neutral
neutral
neutral
pathological
neutral
pathological
pathological
pathological
pathological
4/5 agreement
C611S
D631G
E805K
S819I
R833C
S904C
S904F
pathogenic
pathogenic
benign
pathogenic
pathogenic
pathogenic
pathogenic
disrupted
benign
disrupted
disrupted
benign
benign
benign
Probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
Affects function
affects function
affects function
affects function
affects function
affects function
affects function
neutral
pathological
pathological
neutral
pathological
pathological
pathological
3/5 agreement
Y606C
C531R
G533S
D631A
D631V
R635G
P841L
L881V
K907M
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
benign
pathogenic
benign
benign
benign
benign
benign
benign
benign
disrupted
benign
probably damaging
probablydamaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
tolerated
tolerated
affects function
affects function
affects function
tolerated
tolerated
affects function
affects function
pathological
pathological
neutral
neutral
neutral
pathological
pathological
neutral
neutral
2/5 agreement
C630S
D631E
S649L
H665Q
R844Q
M848T
I852M
K907E
pathogenic
benign
pathogenic
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
probably damaging
tolerated
tolerated
tolerated
tolerated
tolerated
tolerated
affects function
affects function
Neutral
pathological
neutral
pathological
pathological
pathological
neutral
neutral
1/5 agreement
G321R
E511K
D631N
A641S
K666N
R770Q
N777S
V778I
E818K
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
benign
possibly damaging
probably damaging
probably damaging
possibly damaging
benign
possibly damaging
tolerated
tolerated
tolerated
tolerated
tolerated
tolerated
tolerated
affects function
tolerated
pathological
pathological
pathological
neutral
neutral
neutral
neutral
neutral
neutral
aPrimary Sequence Amino Acid Properties (PSAAP) algorithm.
bAnalyzed with default settings at http://mutdb.org/mutpred.
cAnalyzed with default settings at http://genetics.bwh.harvard.edu/pph.
dAnalyzed with default settings at http://sift.jcvi.org.
eAnalyzed with default settings at http://mmb.pcb.ub.es/PMut.
doi:10.1371/journal.pone.0018380.t002
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outcomes of ‘‘pathological’’ or ‘‘neutral’’ and a corresponding
reliability metric (lower is better). Our PSAAP trained algorithm
was in concordance with PMut in 13 benign and 14 pathogenic
predictions for 58% agreement (27 out of 46). The SIFT algorithm
gives outcomes of ‘‘tolerated’’ and ‘‘affects protein function’’. Our
algorithm agreed with SIFT in 19 benign and 16 pathogenic
predictions for 76% agreement (35 out of 46).
Of special interest, for predicted RET benign variants, 7 of 24
agreed across all algorithms, while only 6 of 22 predicted
pathogenic RET variants showed agreement across the different
methods. Although only 13 out of 46 (28%) were concordant,
these variants may count as having a higher degree of confidence
in prediction due to the varied methodologies and basis of
classification. Importantly, the focus of molecular research and
clinical efforts could therefore be directed to this prioritized listing
of RET uncertain variants. Curated variants are shown mapped
across the length of the protein in Figure 2A. This graphing
visually highlights the cysteine rich region just prior to the
transmembrane domain, and the transmembrane domain itself
which contain the majority of pathogenic variants. Our predic-
tions for the uncertain RET variants (VUS) are also mapped by
location across the length of the protein as added into Figure 2B.
Finally, several unpublished RET gene variants with known
pathological (MEN2) outcomes (n=5) were identified during
routine genetic testing at ARUP Laboratories. To further
benchmark a gold standard of truth for RET mutation prediction,
all five algorithms were used to classify this set of not yet seen
variants. Our novel Bayes trained PSAAP classifier correctly
identified all five variants as pathogenic. PMut called 3 disease
causing variants correctly, but classified two others as ‘‘neutral’’
mutations, when in fact these changes were known to be associated
with disease. PolyPhen also correctly identified 3 as probably
damaging (pathogenic), but missed classified the same 2 variants as
PMut. SIFT predicted 4 of these variants would affect function
(pathogenic), but called one of the same variants ‘‘tolerated.’’
MutPred correctly predicted all 5 as pathogenic.
Discussion
Mutations in the RET proto-oncogene have been directly
associated with MEN2 and hereditary medullary thyroid carcino-
ma, and provide guidance for patient care. Accurate classification
of phenotype severity for novel mutations and uncertain variants
as relating to disease is of great importance to proper patient care.
Although correlation of genotype-phenotype offers therapy options
that would otherwise remain hidden and may lead to disease
specific mutation-guided management strategies, appropriate
caution is justified when clinicians are asked to trust computational
outcomes for determining patient care [6].
On-line mutation prediction tools have been available for many
years. Prediction tools such as PolyPhen [13] and SIFT [14] are
primarily based on multiple alignment and amino acid substitution
penalties. More recently, MutPred [9] which calculates probability
Figure 2. Schematic of the RET protein with A) clinically curated variants and B) predicted disease association for uncertain variants
mapped across protein location. The phenotype overlay shows regions of reported MEN2A, MEN2B and FMTC disease.
doi:10.1371/journal.pone.0018380.g002
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Additionally, PMut [15] is neural net based and trained on
human mutations. We recently reported classification of curated
RET gene variants using primary amino acid sequence properties
and Naı ¨ve Bayes [24]. A key feature to highlight is the fact that the
PSAAP algorithm relies on Bayes probability trained on gene-
specific and clinically curated disease outcomes. Comparison of
this recent PSAAP algorithm with established on-line prediction
tools may improve our understanding of predicting mutation
status in the RET proto-oncogene.
Sorting Intolerant From Tolerant (SIFT) was first published in
2003 by Ng and Heinikoff from work done at the Fred Hutchinson
Cancer Research Center in Seattle [14]. The algorithm predicts
whether an amino acid substitution will affect the function of a
protein based on both sequence homology to various orthologs
and physical properties of amino acids. SIFT is a multistep
procedure that (1) searches for and chooses similar sequences (2),
makes an alignment of these sequences, and (3) calculates scores
based on the amino acids appearing at each position in the
alignment. It was initially developed and trained on nsSNP data
sets from LacI, Lysozyme, and HIV protease [25]. This algorithm
works especially well when adequate numbers of sequence
homologs are available for multiple alignment. Conversely, poor
performance is seen when multiple alignment in not reliable or
completely unavailable.
Polymorphism Phenotyping (PolyPhen) is an EMBL based tool
from 2002 from Ramensky et al. [13] It was developed to predict
the possible impact of an amino acid substitution on the structure
and function of a human protein using physical and comparative
considerations. It was originally developed from a set of disease-
causing mutations in human proteins with known structures
extracted from the SWISS-PROT database, and correlated to the
Online Mendelian Inheritance in Man (OMIM) database [26].
Since the algorithm relies on predicted structural disruption, it
works especially well where protein structure is known and less
reliable when a solved protein structure is not available.
MutPred is a recently developed prediction algorithm by Li,
Mooney and Radivojac [9]. It builds on the established SIFT
method but offers improved classification accuracy based upon
protein sequence, and models changes of structural features and
functional sites between wild-type and mutant sequences with
output of probabilities of gain or loss of structure and function. It
was trained on a set of disease SNPs from cancer and the OMIM
disease archive. This predicted disruption of molecular function
again work especially well for well studied proteins, where
homolog and solved structure is available.
PMut was first published in 2005 by the Molecular Modeling
Unit at the Institut de Recerca Biome ´dica, Parc Cientı ´fic de
Barcelona, Spain [15]. It is based on a two layer neural network
and was trained using human mutational data. It allows for either
prediction of single point amino acidic mutations or scanning of
mutational hot spots. Results are obtained by alanine scanning,
identifying massive mutations and genetically accessible mutations.
A graphical interface for Protein Data Bank (PDB) structures,
when available, and a database containing hot spot profiles for all
non-redundant PDB structures are also accessible from the PMut
server.
Benchmarking the established prediction algorithms with
curated RET variants and associated MEN2 disease demonstrates
our PSAAP classifier model compares very well to other
established prediction tools. A distinguishing feature of the PSAAP
model herein reported is the algorithm was trained specifically to
curated RET disease outcomes, as summarized in Figure 3 . This is
in contrast to the less robust curated collections of mutations such
as OMIM or dbSNP. Further, no homolog alignment or solved
protein structure is necessary. Rather, it relies on primary
sequence information only - with calculated delta matrices of
substituted amino acid properties , and is therefore not limited to
scenarios where SIFT or PolyPhen (and others) have traditional
been used. These facts may explain the improved performance
when classifying RET variants as compared to generalized
prediction tools available on-line.
Ranking agreement of predicted phenotype severity across
several complimentary algorithms may provide an additional level
of clinical confidence in computational classifiers. At a minimum,
these five all-in-agreement ‘‘predicted pathogenic’’ RET variants
warrant closer investigation by traditional and molecular tech-
niques. Furthermore, algorithm agreement in a clinical setting
may be just as important for ‘‘benign’’ as it might be for
‘‘pathogenic.’’
Personalized treatment in genomic medicine cannot advance
until questions such as what was found, what does it mean and what to do
about it can be answered for each individual patient and genetic test
result. Among the key features critical for a decision support
framework in clinical genetic testing is a reliable phenotype
classification tool and scoring metric to predict consequences of a
variation that alters protein structure. For these uncertain gene
Figure 3. Overview of the PSAAP classifier workflow, high-
lighting the gene-specific algorithm training on clinically
curated disease association.
doi:10.1371/journal.pone.0018380.g003
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RET curated outcomes seems to outperform well-established and
generalized prediction tools available on-line. More importantly,
agreement between several predictors may provide research
priority for novel and uncertain gene variants.
The use of machine learning algorithms to classify uncertain
gene variants in disease is a promising tool to strengthen our
underlying knowledge of disease pathogenesis. Software algo-
rithms to better classify gene variants of uncertain significance are
necessary to move translational research forward. This follow up
study used the PSAAP algorithm to ‘‘reclassify’’ 46 variants of
uncertain significance within the RET proto-oncogene into
categories of benign or pathogenic. This novel application of
classification algorithms for computational prediction of pheno-
type severity in uncertain gene variants could be generally applied
to any gene-disease setting where a corpus of curated gene variants
are trusted and where reported mutations impact clinical care.
Methods
Non-synonymous RET variants were characterized by physico-
chemical differences in primary amino acid sequence resulting from
the mutation. Attributes of mutation status werecharacterizedusing
values of 544 physical, chemical, conformational, or energetic
properties (AAindex v9.4) [27]. AAindex is a database of numerical
indices representing various physicochemical and biochemical
properties of amino acids and pairs of amino acids. For each RET
variant, matrices of delta values for each biochemical property of
the substituted amino acid were calculated by Python scripting and
the resulting mutation described by an array of variables archived
using SQL - where each matrix corresponds to the absolute value of
the difference between the value of the property in the amino acid
present in the wild type and the one in the mutant.
As previously described, representative algorithms from differ-
ent categories of classification (such as nearest neighbor, bayes,
regression, rule-based and support vector machine) were evaluated
for their ability to correctly predict mutation status in the training
set [24]. Briefly, a clinically curated set (n=84) of non-
synonymous RET mutations with known pathogenicity was used
to train and test machine learning classification algorithms.
Although training and test sets included different disease subtypes
such as MEN2A (n=40), MEN2B (n=3), FMTC (n=5), MEN2A
and FMTC (n=36) - class labels of ‘‘pathogenic’’ and ‘‘benign’’
were used to describe all curated disease association. Random
selection was used to build a 2/3 training set (n=56) and 1/3 test
set (n=28). Attribute selection (feature selection) was performed
during classification training/testing. Machine classification algo-
rithms were implemented using the Weka software package (v3.6)
[28]. When a given classification algorithm produced posterior
probabilities of mutation status, we assigned each variant’s
mutation status according to the higher posterior probability
(Weka’s default behavior).
The PSAAP algorithm performance was evaluated using the test
set, with sensitivity (true positive rate), specificity (true negative
rate), and positive predictive value (precision) calculated. A data
set of non-synonymous RET uncertain variants (n=46) was then
analyzed using our PSAAP (Naı ¨ve Bayes, gene-specific trained)
classification algorithm. The workflow of our PSAAP algorithm is
summarized in Figure 3.
Next, both curated RET mutations (known disease association)
and RET uncertain variants (VUS data) were analyzed and
compared using four existing mutation prediction algorithms.
These established prediction tools are mainly based on phyloge-
netic properties such as sequence homology, amino acid
substitution penalties or structural disruption. MutPred (mutd-
b.org/mutpred) [9], PolyPhen (genetics.bwh.harvard.edu/pph)
[13], SIFT (sift.jcvi.org) [14], and PMut (mmb2.pcb.ub.es:8080/
PMut) [15] were accessed during July/August 2010. Both curated
RET variants and RET VUS entries were evaluated using
respective default settings.
Finally, several unpublished RET disease variants (n=5) with
known pathogenic outcomes (by surgical pathology, molecular
testing and family history) were identified during routine genetic
testing at ARUP Laboratories. This nascent set of RET variants
was also analyzed and compared by all prediction algorithms to
further benchmark some standard of performance and precision.
Data and methods used for this study were approved by the
Institutional Review Board of the University of Utah.
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